SpringWorks Therapeutics Inc (SpringWorks Therapeutics) is a drug development company that develops therapeutic medicines for various diseases. The company’s pipeline products include Nirogacestat, MEK ½ Inhibitor, Senicapoc and FAAH Inhibitor. Its Nirogacestat is a gamma-secretase inhibitor used for the treatment of Desmoid tumors. SpringWorks Therapeutics’ Senicapoc is a Gardos channel blocker used for the treatment of hereditary xerocytosis. The company’s FAAH Inhibitor is used for the treatment of post-traumatic stress disorder. It partners with biopharmaceutical companies, scientists, patient groups and philanthropists. SpringWorks Therapeutics is headquartered in Stamford, Connecticut, the US.
Headquarters
United States of America
Address
100 Washington Blvd, Stamford, Connecticut, 06902-9302
Website
www.springworkstx.com
Telephone
1 203 8839490
No of Employees
305
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SWTX (NASD)
Revenue (2022)
$5.4M
EPS
XYZ
Net Income (2022)
XYZ
-17.2%
(2022 vs 2021)
Market Cap*
$3.2B
Net Profit Margin (2022)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
SpringWorks Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Nirogacestat: Desmoid Tumor |
| Senicapoc: Hereditary Xerocytosis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Others | In March, the company submitted a new drug application to the U.S. Food and Drug Administration for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas. |
| 2023 | Regulatory Approval | In November, the company secured approval from the U.S. Food and Drug Administration for OGSIVEO (nirogacestat), an oral gamma secretase inhibitor to treat adult patients with progressing desmoid tumors who require systemic treatment. |
| 2022 | Contracts/Agreements | In November, the company announced their collaboration with Applied BioMath for the development of a systems pharmacology model in multiple myeloma. |
Competitor Comparison
| Key Parameters | SpringWorks Therapeutics Inc | Azevan Pharmaceuticals Inc | BetaCat Pharmaceuticals Inc | BioXcel Corp | Celgene Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Stamford | Bethlehem | Houston | Branford | Summit |
| State/Province | Connecticut | Pennsylvania | Texas | Connecticut | New Jersey |
| No. of Employees | 305 | - | - | - | - |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Daniel S. Lynch | Chairman | Executive Board | 2019 | 64 |
| Saqib Islam | Chief Executive Officer; Director | Executive Board | 2018 | 53 |
| Francis I. Perier | Chief Financial Officer | Senior Management | 2019 | 63 |
| Badreddin Edris | Chief Operating Officer | Senior Management | 2018 | 36 |
| Daniel Pichl | Chief People Officer | Senior Management | 2020 | 40 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward